Zobrazeno 1 - 10 of 212 pro vyhledávání: '"Mark J, Murphy"'
2
Akademický článek
The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration
Autor: Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer
Publikováno v: Platelets, Vol 33, Iss 1, Pp 147-156 (2022)
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a
Externí odkaz: https://doaj.org/article/021492ffe66347039fb420e397888fd0
Zobrazit plný text záznamu
3
Akademický článek
Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome
Autor: Estelle Gerossier, Saba Nayar, Sylvie Froidevaux, Charlotte G. Smith, Celine Runser, Valentina Iannizzotto, Enrico Vezzali, Gabin Pierlot, Ulrich Mentzel, Mark J. Murphy, Marianne M. Martinic, Francesca Barone
Publikováno v: Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-19 (2021)
Abstract Background Sjögren’s syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immu
Externí odkaz: https://doaj.org/article/61ff86a6cb164b9daf9e959da2dde53e
Zobrazit plný text záznamu
5
Akademický článek
Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus
Autor: Daniel S Strasser, Estelle Gerossier, Virginie Sippel, Ursula Grieder, Andrea Kieninger-Graefitsch, Sylvie Froidevaux, Marten Trendelenburg, Gabin M Pierlot, Enrico Vezzali, Anna K Stalder, Bérengère Renault, Jesper Ryge, Aaron Hart, Ulrich Mentzel, Peter M A Groenen, Marcel P Keller, Marianne M Martinic, Mark J Murphy
Publikováno v: RMD Open, Vol 6, Iss 2 (2020)
Objectives: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phos
Externí odkaz: https://doaj.org/article/74b13847b7f044e2be8ad1ab498686fc
Zobrazit plný text záznamu
6
In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P1) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P1 Receptor Modulator
Autor: Lisa Schlicher, Paulina Kulig, Audrey von Münchow, Mark J. Murphy, Marcel P. Keller
Publikováno v: International Journal of Molecular Sciences, Vol 23, Iss 1191, p 1191 (2022)
International Journal of Molecular Sciences; Volume 23; Issue 3; Pages: 1191
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator currently investigated in a Phase IIb study in patients with systemic lupus erythematosus (SLE) (NCT03742037). S1P1 receptor modulators sequester circulating lymphoc
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e225f551d22cb676b697aa67152686b6
https://www.mdpi.com/1422-0067/23/3/1191
Zobrazit plný text záznamu
8
The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration
Autor: Benoît Lack, Isabelle Guillaumat, Martine Baumann, Markus A. Riederer, Mark J Murphy
Publikováno v: Platelets. 33(1)
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1a83ae140ba37dee956c764c525544
https://pubmed.ncbi.nlm.nih.gov/33427002
Zobrazit plný text záznamu
9
Micron Technology Inc at Deutsche Bank Technology Conference - Final
Publikováno v: Fair Disclosure Wire (Quarterly Earnings Reports). 09/01/2022.
Zobrazit plný text záznamu
10
Akademický článek
MLL becomes functional through intra-molecular interaction not by proteolytic processing.
Autor: Akihiko Yokoyama, Francesca Ficara, Mark J Murphy, Christian Meisel, Chikako Hatanaka, Issay Kitabayashi, Michael L Cleary
Publikováno v: PLoS ONE, Vol 8, Iss 9, p e73649 (2013)
The mixed lineage leukemia (MLL) protein is an epigenetic transcriptional regulator that controls proliferative expansion of immature hematopoietic progenitors, whose aberrant activation triggers leukemogenesis. A mature MLL protein is produced by fo
Externí odkaz: https://doaj.org/article/2ee1c1908c504520b64f99b98bc9750f
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje